Small‑molecule COH-SR4 inhibits adipocyte differentiation via AMPK activation

Figarola,James  L.; Rahbar,Samuel

doi:10.3892/ijmm.2013.1313

Small‑molecule COH-SR4 inhibits adipocyte differentiation via AMPK activation

Authors:
- James L. Figarola
- Samuel Rahbar
View Affiliations

Affiliations: Division of Diabetes, Endocrinology and Metabolism, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA 91010, USA
Published online on: March 21, 2013 https://doi.org/10.3892/ijmm.2013.1313
Pages: 1166-1176

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Obesity is a chronic metabolic disorder caused by an imbalance between energy intake and expenditure. It is one of the principal causative factors involved in the development of metabolic syndrome and cancer. Inhibition of adipocyte differentiation has often been a target of anti-obesity strategies since obesity is caused not only by hypertrophy but also by adipocyte hyperplasia. In this study, we investigated the effects of COH-SR4, a novel compound with anticancer properties, on the adipogenesis in 3T3-L1 cells. Treatment with COH-SR4 significantly inhibited adipocyte differentiation in a dose-dependent manner. This inhibitory effect mainly occurred at the early phase of differentiation through inhibition of mitotic clonal expansion and cell cycle arrest at the G1/S phase transition. In differentiating adipocytes, COH-SR4 significantly reduced intracellular lipid accumulation and downregulated the expression of key adipogenesis-related transcription factors and lipogenic proteins. COH-SR4 exhibited no cytotoxic effects in 3T3-L1 cells, but indirectly activated AMP-activated protein kinase (AMPK). AMPK activation by COH-SR4 also resulted in the phosphorylation of raptor and tuberous sclerosis protein 2 (TSC2), two proteins involved in the mammalian target of rapamycin (mTOR) signaling pathways. Additionally, COH-SR4 decreased the phosphorylation of p70 kDa ribosomal protein S6 kinase (S6K) and initiation factor 4E (eIF4E) binding protein 1 (4EB‑P1), two downstream effectors of mTOR that regulate protein synthesis. Interestingly, knockdown of AMPKα1/α2 prevented the ability of COH-SR4 to inhibit cell cycle arrest and overall adipogenesis and lipid accumulation in the differentiating 3T3-L1 cells. Taken together, these results suggest that COH-SR4 inhibits 3T3-L1 adipogenesis via AMPK activation. COH-SR4 may be a promising compound for the treatment of obesity and related metabolic disorders.

View Figures

View References

1	Grundy SM: Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab. 89:2595–2600. 2004. View Article : Google Scholar : PubMed/NCBI
2	Khandekar MJ, Cohen P and Spiegelman BM: Molecular mechanisms of cancer development in obesity. Nat Rev Cancer. 11:886–895. 2011. View Article : Google Scholar : PubMed/NCBI
3	Jo J, Gavrilova O, Pack S, Jou W, Mullen S, Sumner AE, Cushman SW and Periwal V: Hypertrophy and/or hyperplasia: dynamics of adipose tissue growth. PLoS Comput Biol. 5:e10003242009. View Article : Google Scholar : PubMed/NCBI
4	Pilch PF and Bergenhem N: Pharmacological targeting of adipocytes/fat metabolism for treatment of obesity and diabetes. Mol Pharmacol. 70:779–785. 2006. View Article : Google Scholar : PubMed/NCBI
5	Rosen ED and MacDougald OA: Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol. 7:885–896. 2006. View Article : Google Scholar : PubMed/NCBI
6	Lowe CE, O’Rahilly S and Rochford JJ: Adipogenesis at a glance. J Cell Sci. 124:2681–2686. 2011. View Article : Google Scholar : PubMed/NCBI
7	Tang QQ, Otto TC and Lane MD: Mitotic clonal expansion: a synchronous process required for adipogenesis. Proc Natl Acad Sci USA. 100:44–49. 2003. View Article : Google Scholar : PubMed/NCBI
8	Fajas L: Adipogenesis: a cross-talk between cell proliferation and cell differentiation. Ann Med. 35:79–85. 2003. View Article : Google Scholar : PubMed/NCBI
9	Farmer SR: Transcriptional control of adipocyte formation. Cell Metab. 4:263–273. 2006. View Article : Google Scholar : PubMed/NCBI
10	Hardie DG: AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 25:1895–1908. 2011. View Article : Google Scholar : PubMed/NCBI
11	Carling D, Mayer FV, Sanders MJ and Gamblin SJ: AMP-activated protein kinase: nature’s energy sensor. Nat Chem Biol. 7:512–518. 2011.
12	Steinberg GR and Kemp BE: AMPK in health and disease. Physiol Rev. 89:1025–1078. 2009. View Article : Google Scholar : PubMed/NCBI
13	Villena JA, Viollet B, Andreelli F, Kahn A, Vaulont S and Sul HS: Induced adiposity and adipocyte hypertrophy in mice lacking the AMP-activated protein kinase-alpha2 subunit. Diabetes. 53:2242–2249. 2004. View Article : Google Scholar : PubMed/NCBI
14	Zhang W, Zhang X, Wang H, et al: AMP-activated protein kinase α1 protects against diet-induced insulin resistance and obesity. Diabetes. 61:3114–3125. 2012.
15	Habinowski SA and Witters LA: The effects of AICAR on adipocyte differentiation of 3T3-L1 cells. Biochem Biophys Res Commun. 286:852–856. 2001. View Article : Google Scholar : PubMed/NCBI
16	Giri S, Rattan R, Haq E, Khan M, Yasmin R, Won JS, Key L, Singh AK and Singh I: AICAR inhibits adipocyte differentiation in 3T3L1 and restores metabolic alterations in diet-induced obesity mice model. Nutr Metab. 3:312006. View Article : Google Scholar : PubMed/NCBI
17	Zhou Y, Wang D, Zhu Q, Gao X, Yang S, Xu A and Wu D: Inhibitory effects of A-769662, a novel activator of AMP-activated protein kinase, on 3T3-L1 adipogenesis. Biol Pharm Bull. 32:993–998. 2009. View Article : Google Scholar : PubMed/NCBI
18	Vingtdeux V, Chandakkar P, Zhao H, Davies P and Marambaud P: Small-molecule activators of AMP-activated protein kinase (AMPK), RSVA314 and RSVA405, inhibit adipogenesis. Mol Med. 17:1022–1030. 2011. View Article : Google Scholar : PubMed/NCBI
19	Figarola JL, Weng Y, Lincoln C, Horne D and Rahbar S: Novel dichlorophenyl urea compounds inhibit proliferation of human leukemia HL-60 cells by inducing cell cycle arrest, differentiation and apoptosis. Invest New Drugs. 30:1413–1425. 2012. View Article : Google Scholar
20	Singhal SS, Figarola J, Singhal J, et al: 1,3-Bis(3,5-dichlorophenyl) urea compound ‘COH-SR4′ inhibits proliferation and activates apoptosis in melanoma. Biochem Pharmacol. 84:1419–1427. 2012.
21	Vermeulen K, Van Bockstaele DR and Berneman ZN: The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003. View Article : Google Scholar : PubMed/NCBI
22	Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C and Blenis J: mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol. 24:200–216. 2004. View Article : Google Scholar
23	Laplante M and Sabatini DM: mTOR signaling in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
24	Zoncu R, Efeyan A and Sabatini DM: mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 12:21–35. 2011. View Article : Google Scholar : PubMed/NCBI
25	Ma XM and Blenis J: Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol. 10:307–318. 2009. View Article : Google Scholar : PubMed/NCBI
26	Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE and Shaw RJ: AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 30:214–226. 2008. View Article : Google Scholar : PubMed/NCBI
27	Inoki K, Zhu T and Guan KL: TSC2 mediates cellular energy response to control cell growth and survival. Cell. 115:577–590. 2003. View Article : Google Scholar : PubMed/NCBI
28	Sarbassov DD, Guertin DA, Ali SM and Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
29	Fogarty S and Hardie DG: Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta. 1804:581–591. 2009. View Article : Google Scholar : PubMed/NCBI
30	Menendez JA and Lupu R: Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 7:763–777. 2007. View Article : Google Scholar : PubMed/NCBI
31	Hardie DG: Sensing of energy and nutrients by AMP-activated protein kinase. Am J Clin Nutr. 93:891S–896S. 2011. View Article : Google Scholar : PubMed/NCBI
32	Qiu BY, Turner N, Li YY, et al: High-throughput assay for modulators of mitochondrial membrane potential identifies a novel compound with beneficial effects on db/db mice. Diabetes. 59:256–265. 2010. View Article : Google Scholar : PubMed/NCBI
33	Chen S, Li Z, Li W, Shan Z and Zhu W: Resveratrol inhibits cell differentiation in 3T3-L1 adipocytes via activation of AMPK. Can J Physiol Pharmacol. 89:793–799. 2011.PubMed/NCBI
34	Lee YS, Kim WS, Kim KH, et al: Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 55:2256–2264. 2006. View Article : Google Scholar
35	Rattan R, Giri S, Singh AK and Singh I: 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem. 280:39582–39593. 2005. View Article : Google Scholar : PubMed/NCBI
36	Inoki K, Kim J and Guan KL: AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol. 52:381–400. 2012. View Article : Google Scholar : PubMed/NCBI
37	Laplante M and Sabatini DM: An emerging role of mTOR in lipid biosynthesis. Curr Biol. 19:R1046–R1052. 2009. View Article : Google Scholar : PubMed/NCBI
38	Polak P, Cybulski N, Feige JN, Auwerx J, Rüegg MA and Hall MN: Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell Metab. 8:399–410. 2008. View Article : Google Scholar : PubMed/NCBI
39	Zhang HH, Huang J, Düvel K, et al: Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS One. 4:e61892009. View Article : Google Scholar : PubMed/NCBI
40	Dowling RJ, Topisirovic I, Alain T, et al: mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science. 328:1172–1176. 2010. View Article : Google Scholar : PubMed/NCBI
41	Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M and Borden KL: eIF4E is a central node of an RNA regulon that governs cellular proliferation. J Cell Biol. 175:415–426. 2006. View Article : Google Scholar : PubMed/NCBI
42	Calkhoven CF, Muller C and Leutz A: Translational control of C/EBPalpha and C/EBPbeta isoform expression. Genes Dev. 14:1920–1932. 2000.PubMed/NCBI
43	Rosen ED, Hsu C-H, Wang X, Sakai S, Freeman MW, Gonzalez FJ and Spiegelman BM: C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev. 16:22–26. 2002. View Article : Google Scholar : PubMed/NCBI
44	Yeh WC, Bierer BE and McKnight SL: Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells. Proc Natl Acad Sci USA. 92:11086–11090. 1995. View Article : Google Scholar : PubMed/NCBI
45	Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivières S, Mercep L and Ferrari S: Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem. 273:14424–14429. 1998. View Article : Google Scholar : PubMed/NCBI
46	Cho HJ, Park J, Lee HW, Lee YS and Kim JB: Regulation of adipocyte differentiation and insulin action with rapamycin. Biochem Biophys Res Commun. 321:942–948. 2004. View Article : Google Scholar : PubMed/NCBI
47	El-Chaar D, Gagnon A and Sorisky A: Inhibition of insulin signaling and adipogenesis by rapamycin: effect on phosphorylation of p70 S6 kinase vs eIF4E-BP1. Int J Obes Relat Metab Disord. 28:191–198. 2004. View Article : Google Scholar : PubMed/NCBI
48	Kimura N, Tokunaga C, Dalal S, et al: A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells. 8:65–79. 2003. View Article : Google Scholar : PubMed/NCBI
49	Chiang PC, Lin SC, Pan SL, Kuo CH, et al: Antroquinonol displays anticancer potential against human hepatocellular carcinoma cells: a crucial role of AMPK and mTOR pathways. Biochem Pharmacol. 79:162–171. 2010. View Article : Google Scholar
50	Kalender A, Selvaraj A, Kim SY, et al: Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 11:390–401. 2010. View Article : Google Scholar : PubMed/NCBI